|1.||Koch, Kevin M: 18 articles (01/2015 - 01/2005)|
|2.||Spector, Neil L: 18 articles (01/2015 - 09/2002)|
|3.||Baselga, José: 15 articles (04/2015 - 04/2007)|
|4.||Arteaga, Carlos L: 14 articles (08/2015 - 06/2009)|
|5.||Xia, Wenle: 14 articles (01/2014 - 09/2002)|
|6.||de Azambuja, Evandro: 13 articles (07/2015 - 03/2008)|
|7.||Crown, John: 13 articles (01/2015 - 12/2006)|
|8.||Oliva, Cristina: 12 articles (06/2013 - 12/2006)|
|9.||Osborne, C Kent: 11 articles (09/2015 - 05/2008)|
|10.||Di Leo, Angelo: 11 articles (05/2015 - 12/2008)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer. "
10/01/2015 - "Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation."
02/01/2014 - "In the Irish setting, an adjuvant lapatinib regimen would be considered cost-effective for patients with HER2-positive early-stage breast cancer for four of the five hypothesised hazard ratios. "
06/01/2010 - "Given promising results in clinical studies, we investigated the survival benefits of lapatinib use in patients with HER2-overexpressing advanced or metastatic breast cancer. "
01/03/2012 - "This retrospective single-centre study suggests that the introduction of lapatinib improved survival in patients with BM from HER2-positive breast cancer. "
08/01/2011 - "Treatment with lapatinib beginning 5 days after MNU was highly effective in preventing cancer development. "
12/01/2015 - "Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib."
01/01/2015 - "The above results indicate that lapatinib is effective in decreasing HER2-positive CTCs in patients with MBC irrespectively of the HER2 status of the primary tumor and imply the feasibility of monitoring the molecular changes on CTCs during treatment with targeted agents. "
07/01/2010 - "Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors."
03/01/2014 - "The efficacy of treatments involving lapatinib for patients with metastatic breast cancers was evaluated in a Bayesian metaanalysis of published data from randomized controlled clinical trials. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/2012 - "Lapatinib alone was effective against the multiple liver metastases. "
12/01/2011 - "Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. "
01/01/2010 - "Lapatinib has shown early promise in treatment of central nervous system metastasis and is being further evaluated in various clinical settings. "
08/01/2013 - "The efficacy, safety, and pharmacokinetics of lapatinib 750 mg given twice daily to Japanese HER2-overexpressing MBC patients with brain metastases were assessed as part of the international clinical study. "
11/10/2015 - "Moreover, lapatinib was unexpectedly found to enhance metastasis of TNBC cells, but the underlying mechanisms are not fully understood. "
03/01/2012 - "A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study."
01/01/2015 - "This case report describes treatment of a patient with metastatic lacrimal gland carcinoma with lapatinib, an oral agent with activity against Her-2/neu amplified malignancies. "
01/01/2015 - "Metastatic, her-2 amplified lacrimal gland carcinoma with response to lapatinib treatment."
07/12/2013 - "These findings shed new light on mechanisms involved in lapatinib-mediated autophagy in Her2-expressing breast carcinoma cell lines and in Beclin-1 signaling in these cells. "
07/12/2013 - "We demonstrate that in Her2-expressing breast carcinoma cells that do not succumb to lapatinib, this Her1/2 inhibitor disrupts the cell surface interaction between Her2 and Beclin-1. "
|5.||Stomach Neoplasms (Stomach Cancer)
09/01/2014 - "However, as seen in recent clinical trials, most of HER2+ gastric cancer are actually unresponsive to HER2-targeted agents, including lapatinib. "
06/19/2014 - "Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. "
12/18/2008 - "These results provide a rationale for the future clinical trials of lapatinib combined with cytotoxic drugs in the treatment of HER2-positive gastric cancer."
09/01/2014 - "MET, HER3, IGF1R, and INSR pathways activation represent novel mechanism underlying lapatinib unresponsiveness in HER2+ gastric cancer. "
09/01/2014 - "Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer."
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)